Story perspectives

GLP-1 Drugs Show Promise in Reducing Chronic Migraines

3/2/2026

Summary

Story summary

Glucagon-like peptide-1 (GLP-1) drugs, such as Ozempic, may treat chronic migraines, with users 10% less likely to visit the emergency room and 14% less likely to be hospitalized than topiramate users.
The study involved about 11,000 participants and found GLP-1 users required fewer migraine medications.
Because the study was observational, it cannot establish causality.
Researchers propose anti-inflammatory properties could contribute to the benefits, prompting further research.

1 of 1

Story summary

Glucagon-like peptide-1 (GLP-1) drugs, such as Ozempic, may treat chronic migraines, with users 10% less likely to visit the emergency room and 14% less likely to be hospitalized than topiramate users.
The study involved about 11,000 participants and found GLP-1 users required fewer migraine medications.
Because the study was observational, it cannot establish causality.
Researchers propose anti-inflammatory properties could contribute to the benefits, prompting further research.